Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302157 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
A Phase 1 study, sponsored by Lineage Cell Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02302157 is a Phase 1 study that has completed, run by Lineage Cell Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT02302157, a Phase 1 study, has completed, sponsored by Lineage Cell Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
Interventions
- BIOLOGICAL AST-OPC1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02302157
The ClinicalTrials.gov registry entry for NCT02302157 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lineage Cell Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AST-OPC1 is the first listed.
NCT02302157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02302157 about?
NCT02302157 is a clinical study titled "Dose Escalation Study of AST-OPC1 in Spinal Cord Injury". The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
What is the current status of trial NCT02302157?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-03. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02302157?
The interventions under investigation include: AST-OPC1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02302157?
This trial is sponsored by Lineage Cell Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.